Impact of COVID-19 on 75 Immunocompromised Patients: Does Immunosuppression Alter the Clinical Course?

Document Type : Original Research

Authors
S. Abolghasemi 1
S. Sali 1
D. Yadegarynia 1
R. Gasemi 2
N. Khabiri 1
H. Moradi 1
S. S. Khabiri 3
S. Tehrani 1
1 Infectious diseases and tropical medicine research center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Student Research Committee, School of Medicine, Shahid Beheshti University of medical sciences, Tehran, Iran
3 Taleghani and Imam Ali hospitals clinical research development center, Kermanshah University of Medical Sciences, Kermanshah, Iran
10.52547/iem.7.2.129
Abstract
Backgrounds: Currently, clinical details of immunosuppressed patients suffering from COVID-19 are limited. Some studies have shown no more severe diseases among them, but others have highlighted that immunosuppressed patients may have high levels of viral load and impaired immune responses. Herein, this study aimed to specifically address the symptoms, prognosis, laboratory tests, clinical course, and the outcome of SARS-CoV-2 infected immunocompromised patients at a tertiary referral center.

Materials & Methods: Clinical and laboratory information of 75 non-congenital immunosuppressed patients with COVID-19 disease was obtained at a referral center for immunodeficiency diseases and infectious disorders in Tehran, Iran. Three groups of immunocompromised patients were evaluated, including patients with a history of organ transplantation, autoimmune patients receiving medical therapy, and cancer patients undergoing chemotherapy.

Findings: Among 75 immune-deficient patients with COVID-19, there were 32 patients with a kidney transplant, 23 patients with malignancies, and 19 patients with autoimmune disorders. One patient had both malignancy and multiple sclerosis. The mean length of hospitalization was 10.82 days. By the end of the study, 24 (32%) patients were dead, and 51 (68%) patients were discharged. Dyspnea was the most common (64%) symptom. Low levels of O2 saturation and lymphopenia at admission time significantly affected the mortality rate of patients.

Conclusion: This study showed that mortality rate among immunocompromised patients was 32%. It seems that COVID-19 has a worse outcome and a more severe clinical course in immunocompromised patients regardless of age, gender, and underlying diseases.

Keywords

1. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020;395(10223):507-13.
2. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical characteristics of coronavirus disease 2019 in China. New England journal of medicine. 2020;382(18):1708-20.
3. Yao TT, Qian JD, Zhu WY, Wang Y, Wang GQ. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus—A possible reference for coronavirus disease‐19 treatment option. Journal of medical virology. 2020;92(6):556-63.
4. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020;395(10223):497-506.
5. Al‐Shamsi HO, Alhazzani W, Alhuraiji A, Coomes EA, Chemaly RF, Almuhanna M, et al. A practical approach to the management of cancer patients during the novel coronavirus disease 2019 (COVID‐19) pandemic: an international collaborative group. The oncologist. 2020.
6. Chan KW, Wong VT, Tang SCW. COVID-19: An update on the epidemiological, clinical, preventive, and therapeutic evidence and guidelines of integrative Chinese–Western medicine for the management of 2019 new coronavirus disease. The American journal of Chinese medicine. 2020;48(03):737-62.
7. Emmi G, Bettiol A, Mattioli I, Silvestri E, Di Scala G, Urban ML, et al. SARS-CoV-2 infection among patients with systemic autoimmune diseases. Autoimmunity Reviews. 2020:102575.
8. Lubetzky M, Aull M, Craig-Shapiro R, Lee J, Lee J, Sultan S, et al. Kidney allograft recipients diagnosed with coronavirus disease-2019: a single-center report. medRxiv. 2020.
9. Minotti C, Tirelli F, Barbieri E, Giaquinto C, Donà D. How is immunosuppressive status affecting children and adults in SARS-CoV-2 infection? A systematic review. Journal of Infection. 2020.
10. D'Antiga, LC. Immunosuppressed patients. The 226 facts during the third epidemic. Liver Transpl In press https://227 DOI org/101002/lt.25756.
11. Chen Y, Li L. SARS-CoV-2: virus dynamics and host response. The Lancet Infectious Diseases. 2020;20(5):515-6.
12. Li Y, Xia L. Coronavirus Disease 2019 (COVID-19): Role of Chest CT in Diagnosis and Management. American Journal of Roentgenology. 2020;214(6):1280-6.
13. Organization WH. Coronavirus disease (COVID-19) technical guidance: Laboratory testing for 2019-nCoV in humans. Geneva, Switzerland. 2020.
14. Zhang J, Wang X, Jia X, Li J, Hu K, Chen G, et al. Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China. Clin Microbiol Infect. 2020;26(6):767-72.
15. Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. Covid-19 in critically ill patients in the Seattle region—case series. New England Journal of Medicine. 2020.
16. Kellum JA, Lameire N, Aspelin P, Barsoum RS, Burdmann EA, Goldstein SL, et al. Kidney disease: improving global outcomes (KDIGO) acute kidney injury workgroup. KDIGO clinical practice guideline for acute kidney injury. Kidney international supplements. 2012;2(1):1-138.
17. https://www.healthline.com/health/wbc-count#symptoms-of-an-abnormal-count. [
18. https://www.mayoclinic.org/tests-procedures/hemoglobin-test/about/pac-20385075. [
19. https://www.mayoclinic.org/tests-procedures/liver-function-tests/about/pac-20394595. [
20. https://www.mayoclinic.org/tests-procedures/creatinine-test/about/pac-20384646. [
21. https://www.mayoclinic.org/tests-procedures/c-reactive-protein-test/about/pac-20385228. [
22. Wu Y, Lin H, Xie Q, Chen Q, Huang Y, Zhu Y, et al. COVID-19 in a patient with pre-existing acute lymphoblastic leukemia. Br J Haematol. 2020.
23. He Y, Lin Z, Tang D, Yang Y, Wang T, Yang M. strategic plan for the management of COVID-19 in pediatric hematology and oncology departments. Lancet Haematol. 2020;7(5):e359-e62.
24. Patnaik MM, Lasho T, Padron E, McCullough K, Al-Kali A, Tefferi A, et al. Special considerations in the management of patients with myelodysplastic syndrome / myeloproliferative neoplasm overlap syndromes during the SARS-CoV-2 pandemic. Am J Hematol. 2020.
25. Moujaess E, Kourie HR, Ghosn M. Cancer patients and research during COVID-19 pandemic: A systematic review of current evidence. Crit Rev Oncol Hematol. 2020;150:102972.
26. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. International Journal of infectious diseases. 2020.
27. Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. Int J Infect Dis. 2016;49:129-33.
28. Channappanavar R, Fett C, Mack M, Ten Eyck PP, Meyerholz DK, Perlman S. Sex-Based Differences in Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Infection. J Immunol. 2017;198(10):4046-53.
29. Jaillon S, Berthenet K, Garlanda C. Sexual Dimorphism in Innate Immunity. Clin Rev Allergy Immunol. 2019;56(3):308-21.
30. Dryden M, Baguneid M, Eckmann C, Corman S, Stephens J, Solem C, et al. Pathophysiology and burden of infection in patients with diabetes mellitus and peripheral vascular disease: focus on skin and soft-tissue infections. Clin Microbiol Infect. 2015;21 Suppl 2:S27-32.
31. Akalin E, Azzi Y, Bartash R, Seethamraju H, Parides M, Hemmige V, et al. Covid-19 and kidney transplantation. New England Journal of Medicine. 2020.
32. D'Antiga L. Coronaviruses and immunosuppressed patients: the facts during the third epidemic. Liver Transplantation. 2020.
33. Caselli D, Aricò M. 2019-nCoV: Polite with children! Pediatric reports. 2020;12(1).
34. Shailendra KS. Coronavirus Disease 2019 (COVID-19): Epidemiology, Pathogenesis, Diagnosis, and Therapeutics2020.
35. Hong K-W, Cheong HJ, Choi WS, Lee J, Wie SH, Baek JH, et al. Clinical courses and outcomes of hospitalized adult patients with seasonal influenza in Korea, 2011–2012: Hospital-based Influenza Morbidity & Mortality (HIMM) surveillance. Journal of Infection and Chemotherapy. 2014;20(1):9-14.
36. Alraddadi BM, Watson JT, Almarashi A, Abedi GR, Turkistani A, Sadran M, et al. Risk factors for primary Middle East respiratory syndrome coronavirus illness in humans, Saudi Arabia, 2014. Emerging infectious diseases. 2016;22(1):49.
37. Leung WK, To K-f, Chan PK, Chan HL, Wu AK, Lee N, et al. Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. Gastroenterology. 2003;125(4):1011-7.
38. Assiri A, McGeer A, Perl TM, Price CS, Al Rabeeah AA, Cummings DA, et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. New England Journal of Medicine. 2013;369(5):407-16.
39. Wu J, Liu J, Zhao X, Liu C, Wang W, Wang D, et al. Clinical Characteristics of Imported Cases of Coronavirus Disease 2019 (COVID-19) in Jiangsu Province: A Multicenter Descriptive Study. Clinical Infectious Diseases. 2020.
40. Liu WJ, Zhao M, Liu K, Xu K, Wong G, Tan W, et al. T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV. Antiviral Res. 2017;137:82-92.
41. Guo L, Wei D, Wu Y, ZHOU M, ZHANG X, Li Q, et al. Clinical features predicting mortality risk in patients with viral pneumonia: the MuLBSTA score. Frontiers in microbiology. 2019;10:2752.
42. Ziaie S, Koucheck M, Miri M, Salarian S, Shojaei S, Haghighi M, et al. Review of therapeutic agents for the treatment of COVID-19. Journal of Cellular & Molecular Anesthesia. 2020;5(1):32-6.
43. https://reference.medscape.com/drug/rebetol-ribasphere-ribavirin-342625. ribavirin (Rx): Medscape;
44. Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, et al. T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 2009;82(3):95-102.
45. Zaraket H, Saito R. Japanese surveillance systems and treatment for influenza. Current treatment options in infectious diseases. 2016;8(4):311-28.
46. Jochmans D, van Nieuwkoop S, Smits S, Neyts J, Fouchier R, Van Den Hoogen B. Antiviral activity of favipiravir (T-705) against a broad range of paramyxoviruses in vitro and against human metapneumovirus in hamsters. Antimicrobial agents and chemotherapy. 2016;60(8):4620-9.
Infection Epidemiology and Microbiology
Volume 7, Issue 2
May 2021
Pages 129-140